ADX-629: Clinical Trials

9 trials of ADX-629, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 withdrawn. 9 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 29Completed 8, Withdrawn 1
Phase 12Completed 2

Follow ADX-629: new trials by email Literature Review of ADX-629 trials Research Report on ADX-629

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)
ADX-629 - Alcohol Hepatitis
Phase 2CompletedAldeyra Therapeutics, Inc.42024-11-042026-06-03
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)
ADX-629 (Open-label) - Atopic Dermatitis
Phase 2CompletedAldeyra Therapeutics, Inc.82023-02-152026-11-10
ADX-629 Therapy for Sjogren-Larsson Syndrome
ADX-629 - Sjogren-Larsson Syndrome
Phase 1 / Phase 2CompletedUniversity of Nebraska82023-01-022026-05-05
Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
ADX-629 - Nephrotic Syndrome
Phase 2WithdrawnAldeyra Therapeutics, Inc.2023-01-012024-04-17
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough
ADX-629, Placebo - Chronic Cough
Phase 2CompletedAldeyra Therapeutics, Inc.512022-04-072025-02-28
A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels
ADX-629, Placebo - Ethanol Intoxication
Phase 1 / Phase 2CompletedAldeyra Therapeutics, Inc.262021-11-152025-02-28
A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis
ADX-629 - Plaque Psoriasis
Phase 2CompletedAldeyra Therapeutics, Inc.102021-05-072025-03-11
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.
ADX-629, Placebo - Covid19
Phase 2CompletedAldeyra Therapeutics, Inc.112021-03-312025-02-17
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)
ADX-629, Placebo - Atopic Asthma
Phase 2CompletedAldeyra Therapeutics, Inc.82021-01-092025-02-17

Conditions studied

COVID-19 (1)  ·  Cerebral Palsy (1)  ·  Chronic Cough (1)  ·  Cough (1)  ·  Dermatitis, Atopic (1)  ·  Eczema (1)  ·  Glomerulosclerosis, Focal Segmental (1)  ·  Hepatitis, Alcoholic (1)  ·  Ichthyosis (1)  ·  Inflammation (1)  ·  Intellectual Disability (1)  ·  Muscle Spasticity (1)  ·  Nephrosis, Lipoid (1)  ·  Nephrotic Syndrome (1)  ·  Renal Insufficiency, Chronic (1)

Sponsors

Aldeyra Therapeutics, Inc. (8)  ·  University of Nebraska (1)

Countries

United States (8)  ·  Canada (1)

Top investigators

William B Rizzo, MD (1)

Results publications

PMID 38724717, PMID 39513526